- $2.65bn
- $2.71bn
- $354.34m
- 81
- 25
- 60
- 56
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 209 | 244 | 286 | 336 | 354 |
Cost of Revenue | |||||
Gross Profit | 129 | 143 | 174 | 203 | 213 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 189 | 268 | 273 | 303 | 395 |
Operating Profit | 19.6 | -24.4 | 13.6 | 32.5 | -40.8 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -9.15 | -50.2 | -3.38 | 18.8 | -55.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.93 | -49.4 | -13.3 | 14.7 | -55.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.93 | -49.4 | -13.3 | 14.7 | -55.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.93 | -49.4 | -13.3 | 14.7 | -55.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.038 | -0.343 | -0.035 | 0.008 | -0.188 |
Dividends per Share |